Genmab H1 FY26 operating profit rises 1% to USD 555 million; revenue increases 25% to USD 2.05 billion
PUBT · 1d ago
Share
Listen to the news
- Genmab revenue rose 25% to USD 2.05 billion in the first half of 2026.
- Operating profit edged up to USD 555 million; adjusted operating profit (non-IFRS) increased to USD 656 million.
- Royalty revenue climbed 24% to USD 1.71 billion, driven by higher DARZALEX and Kesimpta royalties.
- Global net sales of EPKINLY/TEPKINLY rose 48% to USD 312 million; cost of product sales increased 51% to USD 149 million.
- Raised 2026 revenue guidance to USD 4.33-4.53 billion; highlighted positive Phase 3 epcoritamab data in relapsed/refractory DLBCL.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending